BREGAL-MILESTONE
Bregal Milestone, a leading European technology and software private equity firm and majority owner of Allshares, a pioneering compensation and long-term incentive software and services provider, today announced the acquisition of Novare Pay and the appointment of Michael Ingelög as Chair of the Allshares Board.
Novare Pay, based in Stockholm, is acclaimed for its reputation as a high-growth, high-margin European compensation services provider with a strong Nordic heritage. With an impressive clientele including leading multinational enterprises, Novare Pay's integration into the Allshares ecosystem will translate to an enhanced end-to-end digital turnkey offering to its over 630 clients spanning more than 40 countries worldwide. The acquisition of Novare Pay further fortifies Allshares' leadership position as one of Europe’s leading compensation software and services providers, with augmented and strengthened capabilities across compensation data and analytics, incentives, and governance. At closing, Novare Pay will rebrand and operate under the Allshares name.
Commenting on the landmark acquisition, Erika Andersson, CEO of Novare Pay, expressed her enthusiasm, stating, "Over the years, we have built a strong and diversified customer footprint and a talented team operating from our strategic hubs in Stockholm, Oslo, and London. Partnering with Allshares presents an exciting opportunity to not only enhance our service delivery with tech-forward compensation software but also to help spearhead a transformative shift in the European compensation landscape."
Cyrus Shey, Co-Founder and Managing Partner at Bregal Milestone, echoed Andersson's sentiments, saying, "We extend a warm welcome to Erika, Andreas, and the entire Novare Pay team as they join the Allshares family. Leveraging Novare Pay's specialized expertise in pay, remuneration, and compensation, alongside its client-centric approach, this partnership will help propel Allshares to new heights across Europe, re-affirming their steadfast commitment to delivering leading compensation solutions that drive high performance for both private and publicly listed customers. With Michael's appointment as Chair, we are confident in our ability to harness this momentum and further strengthen Allshares’ position as an industry leader."
As Chairman Michael Ingelög brings his wealth of experience as a seasoned CEO and board executive with deep knowledge of the Nordic and European markets. In response to his appointment and the acquisition of Novare Pay to the Allshares family, Ingelög commented, “Allshares’ distinctive solutions built and delivered by industry experts underpinned my decision to join as Chair of the Board. With the recent addition of Novare Pay to the Allshares family, Allshares is poised to enhance its offerings even further and truly transform the European compensation landscape. I'm thrilled to help shape the company’s future, alongside management and the board.”
The terms of the transaction were not disclosed and are subject to customary closing conditions.
About Bregal Milestone
Bregal Milestone is a leading European software and technology private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading technology companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €18 billion. Bregal Milestone was recognised by GrowthCap as one of the Top Growth Equity Firms of 2023. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
About Allshares
Allshares is a market leader for equity plan design and administration in the Nordics. Trusted by leading multinational enterprises, Allshares serves approximately 300 multinational public and private enterprise customers in more than 100 countries with an end-to-end digital turnkey solution for equity plan management. Companies and participants can use its proprietary software and services to administer share plans in full compliance with relevant regulations, legal, and tax frameworks, as well as deliver seamless and automated IFRS reporting of share plans to companies. For more information, visit www.allshares.com
About Novare Pay
Novare Pay is a premier provider of remuneration services to multinationals. With a dedicated team of over 50 seasoned specialists stationed across Stockholm, Oslo, and London, Novare Pay offers bespoke compensation services and analytics tailored to clients' needs. Novare Pay boasts an impressive track record of high-growth, high-margin fundamentals, while serving over 900 clients in more than 60 countries. For more information, visit www.allshares.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240512957761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom